Preventing maternal and child deaths, creating an AIDS-free generation, and protecting communities from infectious disease threats needs efficient pharmaceutical services and treatment with quality medicines.
Panagora Group's Monitoring, Evaluation, Research, and Learning (MERL) Activity supports USAID/South Africa’s bilateral Health Office by working collaboratively with health office staff to achieve their overall goals by creatively finding innovative solutions, supplementing and complementing their existing staff capacity, and as appropriate enhancing capacity in performance management; evaluation and research; and systematic collaboration, continuous learning, and adaptive management. We are looking for creative, dynamic, results focused and experienced professionals to be part of a pool of consultants that we can call on to support USAID/South Africa’s bilateral Health Office with a variety of needs in the area of HIV and AIDS.
The PrEP Costing Guidelines provide a framework for estimating the cost of providing pre-exposure prophylaxis (PrEP), which is the use of antiretroviral (ARV) drugs for preventing the acquisition of HIV infection.
Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (TDF
As part of its Monitoring, Evaluation, and Reporting (MER) guidance, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) released Version 2.3 in September 2018, which includes revised indicators for orphans and vulnerable children (OVC) programs.
In our sixth issue, we have assembled 105 abstracts published from October through December 2018 that feature evidence from Botswana (4), Eswatini (5), Lesotho (2), Malawi (8), Mozambique (6), Namibia (2), South Africa (62), Tanzania (1), Zambia (12) and Zimbabwe (10).
There has been a notable expansion in routine health care in sub-Saharan Africa. While heath care is nominally free in many contexts, the time required to access services reflects an opportunity cost that may be substantial and highly gendered, reflecting the gendered nature of health care guidelines and patterns of use. The time costs of health care use, however, have rarely been systematically assessed at the population-level.
In this five-minute video, Vuyiseka Dubula-Majola – director at Stellenbosch University’s Africa Centre for HIV/AIDS, who is well recognized for her activism to ensure affordable access to health services for people living with HIV – gives her perspective on what it will take for Afri